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Background: Metabolic syndrome (coexisting visceral obesity, dyslipidemia, hyperglycemia, and hypertension) is a
prominent risk factor for cardiovascular morbidity and mortality, however, its effect on cardiac gene expression
pattern is unclear. Therefore, we examined the possible alterations in cardiac gene expression pattern in male
Zucker Diabetic Fatty (ZDF) rats, a model of metabolic syndrome.
Methods: Fasting blood glucose, serum insulin, cholesterol and triglyceride levels were measured at 6, 16, and
25 wk of age in male ZDF and lean control rats. Oral glucose tolerance test was performed at 16 and 25 wk of age.
At week 25, total RNA was isolated from the myocardium and assayed by rat oligonucleotide microarray for 14921
genes. Expression of selected genes was confirmed by qRT-PCR.
Results: Fasting blood glucose, serum insulin, cholesterol and triglyceride levels were significantly increased,
glucose tolerance and insulin sensitivity were impaired in ZDF rats compared to leans. In hearts of ZDF rats,
36 genes showed significant up-regulation and 49 genes showed down-regulation as compared to lean controls.
Genes with significantly altered expression in the heart due to metabolic syndrome includes functional clusters of
metabolism (e.g. 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2; argininosuccinate synthetase; 2-amino-3-
ketobutyrate-coenzyme A ligase), structural proteins (e.g. myosin IXA; aggrecan1), signal transduction (e.g. activating
transcription factor 3; phospholipase A2; insulin responsive sequence DNA binding protein-1) stress response
(e.g. heat shock 70kD protein 1A; heat shock protein 60; glutathione S-transferase Yc2 subunit), ion channels and
receptors (e.g. ATPase, (Na+)/K+ transporting, beta 4 polypeptide; ATPase, H+/K+ transporting, nongastric, alpha
polypeptide). Moreover some other genes with no definite functional clusters were also changed such as e.g. S100
calcium binding protein A3; ubiquitin carboxy-terminal hydrolase L1; interleukin 18. Gene ontology analysis revealed
several significantly enriched functional inter-relationships between genes influenced by metabolic syndrome.
Conclusions: Metabolic syndrome significantly alters cardiac gene expression profile which may be involved in
development of cardiac pathologies in the presence of metabolic syndrome.
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It is well established that metabolic syndrome is a major
risk factor for cardiovascular diseases [1-4]. Metabolic
syndrome is defined as the coexistence of visceral obesity,
dyslipidemia, hyperglycemia, and hypertension [5,6]. Most
individuals with metabolic syndrome have abdominal
obesity and develop insulin resistance, therefore the preva-
lence of metabolic syndrome and pre-diabetes overlap
[7,8]. In addition, metabolic syndrome can be considered as
a direct precursor state of diabetes mellitus type 2 [7,9] and
cardiovascular diseases [7,10]. Moreover, the efficacy of car-
dioprotective interventions (i.e. pre- and postconditioning)
seems to be diminished in the presence of pathological
conditions associated with metabolic syndrome [11-13]
such as obesity [14], diabetes [15-18] or dyslipidemia
[19,20]. Metabolic syndrome affects a large population
including all ages from children to elderly and both sexes
worldwide [21-23]. According to the Third National Health
and Nutrition Examination Survey (NHANES III) criteria,
about 47 million people (approximately 24% of the US
adult population) had metabolic syndrome in the USA in
2002 [24]. Its prevalence is raising both in developed
[21,24], and in developing countries [21,24]. In addition,
patients suffering from metabolic syndrome have an
approximate 5-fold increase in diabetes risk compared with
persons without metabolic syndrome [7,25]. The effect of
metabolic syndrome on gene expression pattern in various
tissue types has been investigated in a few studies. In insulin
sensitive tissues (liver, skeletal muscle and adipose tissue)
[26] and pancreatic β-cells [27] obtained from the well-
known metabolic syndrome model (Zucker Diabetic Fatty
rat, ZDF), altered gene expression pattern were shown
when compared to their controls. However, the effect of
metabolic syndrome on the gene expression pattern of the
heart has not been investigated yet.
Therefore, our aim was in the present study to investi-
gate the effect of metabolic syndrome on cardiac gene
expression pattern in male ZDF rats.
Materials and methods
This investigation conforms to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals
(NIH Pub. No. 85-23, Revised 1996) and was approved by
the Animal Research Ethics Committee of the University of
Szeged.
Male Zucker Diabetic Fatty (ZDF/Gmi-fa/fa) rats and
their lean controls were obtained from Charles River La-
boratories at the age of 5 weeks and were housed at 22±2°C
with a 12:12-h light-dark cycle. The rats received Purina
5008 chow and water ad libitum for 20 weeks after their
arrival.
The Zucker diabetic fatty (ZDF) rat with a point mutation
in the leptin receptor is a recognized model of obesity,
hyperlipidemia, hyperglycemia and hypertension [28-30]. Inthe present study, only male rats were used, since female
ZDF rats are less prone to the development of metabolic
syndrome [31,32]. Male ZDF rats develop an age-
dependent obese and hyperglycemic phenotype at 10-12
weeks of age accompanied by a metabolic state of obesity,
dyslipidemia, hyperinsulinemia and insulin resistance
[33,34] which develops to a hyperglycemic insulin-deficient
state [33]. The metabolic features manifested in this animal
model are in many ways similar to the pathogenesis of
metabolic syndrome in humans [33,35]. Therefore, the
ZDF rat is an ideal model for investigation of cardiac gene
expression pattern changes related to human metabolic
syndrome.
Experimental setup
Body weight, serum glucose, insulin, cholesterol and
triglyceride levels and homeostasis model assessment-
estimated insulin resistance (HOMA-IR) were determined
at 6, 16 and 25 weeks of age in order to monitor the basic
parameters of glucose and lipid metabolism and insulin
resistance in ZDF and lean rats (Figure 1). Oral glucose
tolerance test (OGTT) was performed at week 16 and 25 in
order to further characterize glucose homeostasis in ZDF
and lean rats (Figure 1). At 25 weeks of age, rats were
anaesthetized using diethyl ether. Hearts and pancreata
were isolated (Figure 1), and then hearts were perfused
according to Langendorff as described earlier [36]. After
10 min perfusion ventricular tissue was frozen and stored
at -80°C until DNA microarray investigation and gene
expression analysis (Figure 1). To validate the well-
known nitrosative stress-inducing effect of metabolic
syndrome on the heart, frozen ventricular tissue was
used for determination of cardiac free 3-nitrotyrosine
level (Figure 1).
Serum glucose level measurements and OGTT
Rats were fasted overnight (12 h) prior to serum glucose
level measurements (week 6, 16 and 25) and OGTTs
(week16 and 25) to verify the development of hypergly-
cemia as a diagnostic criterion of metabolic syndrome.
Blood samples were collected from the v. saphena. Blood
glucose levels were measured using AccuCheck blood glu-
cose monitoring systems (Roche Diagnostics Corporation,
USA, Indianapolis). In case of OGTT, after the measure-
ment of baseline glucose concentrations, a standard dose of
glucose (1.5 g/kg body weight) was administered per os via
gavage and plasma glucose levels were checked 30, 60 and
120 minutes later. Area under the curve values for OGTT
was also calculated.
Measurement of serum and pancreatic insulin levels
Serum and pancreatic insulin levels were measured by
an enzyme immunoassay (Mercodia, Ultrasensitive Rat
Insulin ELISA) in order to verify the development of
03
6
9
wk 6 wk 16 wk 25
Se
ru
m
 tr
ig
lic
er
id
e
(m
m
ol
/L
)
B) C) D)
0
200
400
600
wk 6 wk 16wk 25
An
im
a
l w
ei
gh
t (g
)
F)E)
0
1
2
3
4
wk 6 wk 16wk 25
Se
ru
m
 c
ho
le
st
er
ol
(m
m
ol
/L
)
G)
Lean
ZDF
Lean/ZDF
6 16 25wk BW, Se Glu, Insulin, Chol, TG 
OGTT
Pancreatic insulin
# Heart isolation, DNA chip, 3-nitrotyrosine#
0
50
100
150
200
250
wk 6 wk 16 wk 25
H
O
M
A 
IR
(µl
U/
ml
*
m
m
ol
/l)
0
5
10
15
wk 6 wk 16 wk 25
Se
ru
m
 g
lu
co
se
(m
m
ol
/L
)
0
5
10
15
20
25
wk 6 wk 16 wk 25
Se
ru
m
 in
su
lin
(µg
/L)
A)
Figure 1 Experimental protocol (A) Male Zucker Diabetic Fatty (ZDF) rats and their lean controls were followed up from 6 weeks of
age until 25 weeks of age. Body weight (BW), serum glucose (Se Glu), insulin (Insulin), cholesterol (Chol) and triglyceride (TG) levels were
determined at week 6, 16 and 25. Oral glucose tolerance test (OGTT) was performed at week 16 and 25. At week 25, hearts and pancreata were
isolated. Pancreata were frozen and homogenized to measure pancreatic insulin levels. Hearts were perfused according to Langendorff for 10
minutes using Krebs-Henseleit buffer. Then ventricular tissue was frozen and used for DNA microarray analysis and cardiac free 3-nitrotyrosine
level measurements. Serum glucose (B, n=6-8) and insulin levels (C, n=6-8), HOMA-IR (D), animal weight (E), serum cholesterol (F, n=6-8) and
triglyceride (G, n=6-8) shown at week 6, 16 and 25 in both lean and ZDF rats. Solid line: Lean; dashed line: ZDF. Values are means±SEM, *p<0.05.
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http://www.cardiab.com/content/12/1/16hyperinsulinemia and decreased pancreatic insulin content
as a consequence of beta cell damage in metabolic
syndrome. Insulin ELISA was carried out according to
the instructions of the manufacturer from either sera or
homogenized pancreatic tissue samples of ZDF and lean
control rats. Sera were centrifuged (4500 rpm for 10 min
at 4°C) and kept at -20°C until further investigation.
Pancreata were removed, trimmed free of adipose tissue
and weighed. Pancreata were homogenized in 6 ml cold
acidified-ethanol (0.7 M HCl: ethanol (1:3 v/v) with an
Ultraturrax homogenizer and were kept at 4°C for 24 h.
Then pancreas homogenates were centrifuged (900 g for
15 min at 4°C), and the supernatants were stored at 4°C.
The pellet was extracted again with 3 ml acidified
ethanol for 24 h at 4°C. The supernatant obtained after
centrifugation was pooled with the previous one and
kept at -20°C until assayed.HOMA-IR index
To estimate insulin resistance in ZDF or lean rats the
widely used HOMA-IR index was calculated [37-39]
by multiplying fasting plasma insulin (μIU/mL) with
fasting plasma glucose (mmol/L), then dividing by
the constant 22.5, i.e. HOMA-IR = (fasting plasma
insulin concentration×fasting plasma glucose concen-
tration)/22.5.Measurement of serum lipid levels
Serum cholesterol and triglyceride levels were measured
at week 6, 16 and 25 using a test kit supplied by
Diagnosticum Zrt. (Budapest, Hungary) as described
previously [40] in order to follow up the development of
hyperlipidemia which is a diagnostic criterion of meta-
bolic syndrome.
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Figure 2 Glucose levels during OGTT. Glucose levels during OGTT at week 16 (A) and week 25 (B) in both lean and ZDF rats. Solid line: Lean;
dashed line: ZDF. Values are means±SEM, n=6-8, *p<0.05.
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http://www.cardiab.com/content/12/1/16Cardiac 3-nitrotyrosine level, an indicator of myocardial
nitrosative stress
To verify the well-known increased oxidative/nitrosative
stress [41,42] in the heart in metabolic syndrome, cardiac
free 3-nitrotyrosine level, an indirect marker of nitrosative
stress, was measured by ELISA (Cayman Chemical) from
ZDF and lean control heart tissue samples at week 25 as
described earlier [40]. Briefly, supernatants of ventricular
tissue homogenates were incubated overnight with anti-
nitrotyrosine rabbit IgG specific to free 3-nitrotyrosine
and nitrotyrosine acetylcholinesterase tracer in precoated
(mouse anti-rabbit IgG) microplates followed by develop-
ment with Ellman's reagent. Free nitrotyrosine content was
normalized to protein content of the cardiac homogenate
and expressed as nanograms per milligram protein [40].
RNA preparation
Total RNA was purified from whole heart of Zucker
Diabetic Fatty (ZDF) and lean control rats (n=6-8 in each
group) using an RNA isolation kit (Macherey-Nagel, Düren,
Germany). All the preparation steps were carried out
according to the manufacturer’s instructions. RNA samples
were stored at –80°C in the presence of 30 U Prime RNAseA) B
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Figure 3 Pancreas weight and pancreas insulin content. Pancreas weig
ZDF rats. Values are means±SEM, n=6-8, *p<0.05.inhibitor (Fermentas, Lithuania) untill further analysis. The
quantity of isolated RNA samples was checked by spectro-
photometry (NanoDrop 3.1.0, Rockland, DE, USA).
DNA microarray analysis
Total RNAs (1 μg) were first reverse transcribed in 10 μl
volume using Oligo(dT) Primer and ArrayScript enzyme
as described previously [43]. Than the second cDNA
strand was synthesized in 50 μl final volume using DNA
Polymerase and RNase H. Amino allyl modified aRNA
were than synthesized by In Vitro Transcription using
aaUTP and T7 Enzyme mix. All these steps were done
using AminoAllyl MessageAmpTM II aRNA Amplifica-
tion Kit (Ambion, USA), according to manufacturer’s
instructions. Six μg of amino allyl modified amplified RNA
were labeled with either Cy5 or Cy3 dyes in 10 μl volume
according to the manufacturer’s instructions (Ambion,
USA), than purified using RNA purification columns
(Macherey Nagel, Düren, Germany).
Rat microarray of 8-plex format from Agilent Tech-
nologies (Palo Alto, CA, USA) was used to determine
gene expression changes in the hearts of ZDF rats com-
pared to lean controls. Each matrix contains ~15.000)
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http://www.cardiab.com/content/12/1/16oligonucleotides corresponding to different genes and
control sequences. 300 ng of Cy5 and Cy3 labeled RNA
in 19 μl volume, 5 μl 10X Blocking Agent and 1 μl
25X Fragmentation Buffer were mixed together and
incubated at 60°C for 30 minutes. 25 μl 2X GEx
Hybridization Buffer were added to each sample, to
stop the fragmentation reaction. All these steps were
done using Gene expression hybridization kit (Agilent
Technologies, Palo Alto, CA). 48 μl of these mixes
were used for the hybridization, which was done in
microarray hybridization chambers (Agilent Technologies,
Palo Alto, CA). The chambers were then loaded into a
hybridization rotator rack (~5 rpm) and incubated at 65°C
for 17 hours. After hybridization the slides were washed in
Wash buffer 1 from Agilent Technologies at room
temperature for 1 minute than in Wash buffer 2 at 37°C
for another 1 minutes before scanning. Each array was
scanned at 543 nm (for Cy3 labeling) or at 633 nm (for
Cy5 labeling) in Agilent Scanner using the built-in
Extended Dynamic Range function with 5 μm reso-
lution. Output image analysis and feature extraction
was done using Feature Extraction 9.5.1 software of
Agilent Technologies.0
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Figure 4 Myocardial 3-nitrotyrosine level. Myocardial 3-
nitrotyrosine level at week 25 in both lean and ZDF rats. Values are
means±SEM, *p<0.05.Quantitative real-time PCR (QRT-PCR)
In order to validate gene expression changes obtained
by DNA microarray, QRT-PCR was performed on a
RotorGene 3000 instrument (Corbett Research, Sydney,
Australia) with gene-specific primers and SybrGreen
protocol to monitor gene expression as described earlier
[44,45]. Briefly, 2 μg of total RNA was reverse transcribed
using the High-Capacity cDNA Archive Kit (Applied
Biosystems Foster City, CA, USA) according to the manu-
facturer’s instructions in a final volume of 30 μL. After dilu-
tion with 30 μL of water, 1 μL of the diluted reaction mix
was used as template in the QRT- PCR with FastStart SYBR
Green Master mix (Roche Applied Science, Mannheim,
Germany) with the following protocol: 10 min at 95°C fol-
lowed by 45 cycles of 95°C for 15 sec, 60°C for 25 sec and
72°C for 25 sec. The fluorescence intensity of SybrGreen
dye was detected after each amplification step. Melting
temperature analysis was done after each reaction to check
the quality of the products. Primers were designed using
the online Roche Universal Probe Library Assay Design
Center. The quality of the primers was verified by MS
analysis provided by Bioneer (Daejeon, Korea). Relative
expression ratios were calculated as normalized ratios to rat
HPRT, GAPDH and Cyclophyllin genes. Non-template
control sample was used for each PCR run to check
primer-dimer formation. The final relative gene expres-
sion ratios were calculated as delta-delta Ct values. Fold
change refers to 2-ΔΔCt (in the case of up-regulated genes)
and –(1/2-ΔΔCt) (in the case of down-regulated genes).Gene ontology (GO) analysis
By using DNA microarrays for transcriptional profiling a
large number of genes can be analyzed simultaneously [46],
however, resulting data do not give direct information
about biological interaction of the differentially expressed
genes. GO analysis is a suitable method for integration
genes with pathways and biological interaction networks to
detect coordiated changes in functionally related genes. GO
analysis was performed using GO/pathway analysis using
the open access software DAVID bioinformatics system
and database (Database for Annotation, Visualization and
Integrated Discovery, http://david.abcc.ncifcrf.gov). The
differentially expressed genes were submitted to DAVID
bioinformatics system and database to reveal significantly
enriched biological functions/pathways.
Statistical analysis
For characterization of the ZDF model and lean controls,
all values (body weight, serum glucose, insulin, HOMA-IR,
cholesterol and triglyceride levels, pancreas weight and
insulin content and myocardial 3-nitrotyrosine levels) are
presented as mean±SEM. Significance between groups was
determined with two sample t-test. P<0.05 was accepted as
a statistically significant difference.
In the microarray experiments, dye swap parallel labeling
was applied to eliminate dye induced biases. Biological and
technical replica experiments were carried out to gain raw
data for statistical analysis. Altogether 4 individual parallel
gene activity comparisons were done. Statistical analysis
was performed to get reliable data. Using two tailed two
sample unequal variance Student t-test, the p-value was
Table 1 Down-regulated genes on DNA microarray
Gene function Description [Gene symbol] Acc. No.: AVE log2 SD P value Fold change
Metabolism Argininosuccinate synthetase [Ass] NM_013157 −1.33 0.06 0.001 −2.51
Glycine C-acetyltransferase (2-amino-3-
ketobutyrate-coenzyme A ligase) [Gcat]
NM_001024277 −1.15 0.34 0.006 −2.22
3-hydroxybutyrate dehydrogenase, type 1 [Bdh1] NM_053995 −1.14 0.44 0.014 −2.21
Thymidylate synthase [Tyms] NM_019179 −0.92 0.08 0.041 −1.89
Dicarbonyl L-xylulose reductase [Dcxr] NM_134387 −0.76 0.30 0.015 −1.70
Stress response Heat shock 70kd protein 1A [Hspa1a] NM_031971 −1.84 0.48 0.005 −3.59
Similar to 60 kDa heat shock protein, mitochondrial
precursor (Hsp60) 60 kda heat shock protein
[LOC294396]
XR_085659 −1.64 0.24 0.057 −3.11
Interleukin 18 [il18] NM_019165 −1.38 0.02 0.007 −2.60
Signal transduction,
regulation of
transcription
Hairy/anhancer-of-split-related with YRPW motif2
[Hey2]
NM_130417 −1.40 0.15 0.049 −2.64
Aryl hydrocarbon receptor nuclear translocator-like
[Adra1d]
NM_024362 −1.33 0.07 0.001 −2.52
Activating transcription factor 3 [Atf3] NM_012912 −1.03 0.26 0.004 −2.05
RAB7, member RAS oncogene family [Rab7] NM_023950 −0.98 0.48 0.026 −1.97
B-cell leukemia/lymphoma 2 related protein A1
[Bcl2a1]
NM_133416 −0.89 0.04 0.019 −1.85
Sushi, nidogen and EGF-like domains 1 [Sned1] XM_237415 −0.87 0.51 0.041 −1.83
Spermatid perinuclear RNA binding protein [Strbp] NM_053416 −0.87 0.25 0.027 −1.82
TRAF3 interacting protein 3 [Traf3ip3] NM_001014132 −0.85 0.25 0.028 −1.81
Putative bhlh transcription factor (Fragment) [Ascl3] ENSRNOT00000018309 −0.79 0.15 0.013 −1.73
Membrane
proteins, receptors
Atpase, (Na+)/K+ transporting, beta 4 polypeptide
[Atp1b4]
NM_053381 −1.38 0.13 0.003 −2.60
Nerve growth factor receptor (TNFR superfamily,
member 16) [Ngfr]
NM_012610 −0.91 0.05 0.027 −1.88
Cholinergic receptor, nicotinic, gamma polypeptide
[Chrng]
NM_019145 −0.99 0.39 0.048 −1.98
G protein-coupled receptor 37 [Gpr37] NM_057201 −0.87 0.06 0.030 −1.82
Adrenergic receptor, alpha 1d [Adra1d] NM_024483 −0.79 0.43 0.036 −1.73
Neurotensin receptor 2 [Ntsr2] NM_022695 −0.77 0.32 0.018 −1.70
Structural protein,
cell adhesion
Myosin ixa [myo9a] NM_134335 −1.26 0.01 0.002 −2.40
ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 4 [St8sia4]
NM_053914 −1.00 0.07 0.032 −2.01
Similar to collagen, type XXIV, alpha 1
[RGD1565539_predicted]
XM_575056 −1.16 0.03 0.011 −2.24
Others ADAM metallopeptidase with thrombospondin
type 1 motif, 1 [Adamts1]
NM_024400 −2.84 0.90 0.1230 −7.16
Similar to tatd dnase domain containing 1
[RGD1566244_predicted]
XR_007720 −1.86 0.16 0.038 −3.63
Aryl hydrocarbon receptor nuclear translocator-like
protein [Arntl]
NM_024362 −1.33 0.67 0.001 −2.52
TAF13 RNA polymerase II, TATA box binding
protein (TBP)-associated factor [Taf13_predicted]
ENSRNOT00000027530 −1.22 0.11 0.039 −2.34
G protein-coupled receptor 107
[Gpr107_predicted]
ENSRNOT00000037742 −1.18 0.02 0.007 −2.26
CDK5 regulatory subunit associated protein 1-like 1
[Cdkal1_predicted]
XM_341524 −0.92 0.06 0.041 −1.89
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Table 1 Down-regulated genes on DNA microarray (Continued)
Similar to chondroitin beta1,4 N-
acetylgalactosaminyltransferase 2
[RGD1563660_predicted]
ENSRNOT00000019778 −0.91 0.03 0.017 −1.87
S100 calcium binding protein A3 [S100a3] NM_053681 −0.90 0.06 0.028 −1.87
Similar to TPR repeat-containing protein KIAA1043
[LOC304558]
XM_222260 −0.89 0.08 0.003 −1.85
Similar to Ten-m4 [Odz4_predicted] ENSRNOT00000015181 −0.88 0.34 0.047 −1.84
Kallikrein 14 [Klk14_predicted] ENSRNOT00000029197 −0.88 0.09 0.047 −1.84
Mucin 19 [Muc19_predicted] XM_235593 −0.84 0.33 0.048 1.79
Copine family member IX [Cpne9] NM_001024982 −0.84 0.11 0.006 −1.79
Suppressor of Ty 16 homolog (S. Cerevisiae)
[Supt16h_predicted]
XM_223981 −0.81 1.57 0.021 −1.75
Heterogeneous nuclear ribonucleoprotein L-like
[Hnrpll_predicted]
XM_233805 −0.81 0.01 0.008 −1.75
Cdna clone UI-R-BJ0p-afn-b-03-0-UI 3' [Sln] CK841541 −0.81 0.30 0.013 −1.75
Discs, large homolog 4 (Drosophila) [Dlgh4] NM_019621 −0.80 0.23 0.026 −1.75
Similar to chondroitin beta1,4 N-
acetylgalactosaminyltransferase
[RGD1307618_predicted]
XM_224757 −0.80 0.25 0.031 −1.74
Sterile alpha motif domain containing 4
[Samd4_predicted]
ENSRNOT00000060847 −0.80 0.02 0.012 −1.74
Similar to RIKEN cdna 1190005B03
[Cdkal1_predicted]
ENSRNOT00000024854 −0.79 0.06 0.035 −1.73
WDNM1 homolog [LOC360228] NM_001003706 −0.78 0.24 0.007 −1.72
CD300 antigen like family member E
[Cd300le_predicted]
XR_009489 −0.78 0.362 0.023 −1.71
Neuronatin [nnat] NM_053601 −0.77 0.35 0.022 −1.71
Connective tissue growth factor [Ctgf] NM_022266 −0.77 0.47 0.049 −1.69
Chemokine (C-X-C motif) ligand 11 [Cxcl11] NM_182952 −0.75 0.17 0.003 −1.68
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changes. Gene expression ratio with p- value < 0.05 and
log2 ratio < -0.75 or log2 ratio > 0.75 (~1.7 fold change) are
considered as repression or overexpression respectively in
gene activity.
Results
Characterization of metabolic syndrome
In order to verify the development of metabolic syndrome
in male ZDF rats, concentrations of several plasma metabo-
lites and body weight were measured at week 6, 16 and 25
(Figure 1). ZDF rats showed a significant rise in serum
fasting glucose level starting from week 16 as compared to
lean controls (Figure 1B). Parallel with hyperglycemia,
serum insulin levels were significantly increased in ZDF rats
compared to lean ones during the 25 weeks showing the
presence of hyperinsulinemia in ZDF animals (Figure 1C).
However, serum insulin concentration in ZDF rats was
significantly lower at week 25 as compared to serum insulin
level measured at week 16 indicating beta-cell damage.
HOMA IR was significantly higher at week 6, 16 and 25 in
ZDF rats when compared to lean controls showing insulinresistance in ZDF animals (Figure 1D). Body weight
increased throughout the study and was significantly higher
in ZDF animals compared to lean ones showing obesity
(Figure 1E). Both serum cholesterol and triglyceride levels
were significantly increased in ZDF rats as compared to
lean ones throughout the study duration representing
hyperlipidemia (Figure 1F and 1G). Oral glucose tolerance
test (OGTT) was performed at week 16 and 25 in order to
verify the development of impaired glucose tolerance in
ZDF rats. Glucose levels during OGTTs were markedly
increased in ZDF rats in every time point of blood glucose
measurements both at weeks 16 and 25 (Figure 2A-2B).
Area under the curve (AUC) of blood glucose concen-
tration during OGTTs was significantly elevated in ZDF
rats at both weeks 16 and 25 (1520±96 vs. 757±13 and
2692±129 vs. 741±21, respectively) representing impaired
glucose tolerance.
Pancreas weight and pancreatic insulin content were
measured at the end of the experiment in order to
investigate the severity of diabetes mellitus in ZDF
rats. Pancreas weight and pancreatic insulin concen-
tration were significantly decreased in ZDF rats at
Table 2 Up-regulated genes on DNA microarray
Gene function Description [Gene symbol] Acc. No.: AVE log2 SD P value Fold change
Metabolism Acyl-coa thioesterase 7 [Acot7] NM_013214 0.75 0.34 0.021 1.69
Angiopoietin-like 4 [Angptl4] NM_199115 0.83 0.25 0.007 1.78
Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme C
[Mgat4c_predicted]
ENSRNOT00000005523 0.87 0.29 0.037 1.82
Carbonyl reductase 1 [Cbr1] NM_019170 0.99 0.40 0.016 1.99
3-hydroxy-3-methylglutaryl-Coenzyme A synthase
2 [Hmgcs2]
NM_173094 1.05 0.25 0.004 2.07
Transglutaminase 1 [tgm1] NM_031659 1.35 0.13 0.044 2.55
Cytosolic acyl-coa thioesterase 1 [Cte1] NM_031315 1.88 0.41 0.003 3.69
Stress response Cold inducible RNA binding protein [Cirbp] NM_031147 0.77 0.21 0.005 1.71
Glutathione S-transferase Yc2 subunit [Yc2] NM_001009920 0.86 0.16 0.002 1.82
Signal transduction,
regulation of
transcription
Calcium/calmodulin-dependent protein kinase II
gamma [Camk2g]
NM_133605 0.75 0.21 0.006 1.68
Phospholipase A2, group VII (platelet-activating
factor acetylhydrolase, plasma) [Pla2g7]
NM_001009353 1.45 0.84 0.041 2.74
Brain expressed X-linked 1 [Bex1] NM_001037365 0.92 0.57 0.048 1.90
Fibroblast growth factor receptor substrate 3 [Frs3] NM_001017382 1.05 0.04 0.018 2.07
Membrane proteins,
receptors
Huntingtin-associated protein 1 [Hap1] NM_024133 0.77 0.29 0.043 1.71
Membrane protein, palmitoylated 3 (MAGUK p55
subfamily member 3) [RGD1560049_predicted]
ENSRNOT00000055194 1.10 0.45 0.016 2.15
Atpase, H+/K+ transporting, nongastric, alpha
polypeptide [Atp12a]
NM_133517 1.39 0.19 0.006 2.61
Structural protein, cell
adhesion
Spectrin beta 3 [Spnb3] NM_019167 0.95 0.05 0.026 1.93
Aggrecan 1 [agc1] NM_022190 1.06 0.09 0.037 2.08
Others Similar to mucin 7, salivary
[RGD1311530_predicted]
ENSRNOT00000014519 0.75 0.22 0.007 1.69
Leukocyte tyrosine kinase [Ltk_predicted] ENSRNOT00000050055 0.77 0.04 0.021 1.70
Similar to RIKEN cdna 9130022B02
[Pck2_predicted]
ENSRNOT00000025260 0.78 0.28 0.042 1.72
Similar to hypothetical protein [Arid2_predicted] ENSRNOT00000006970 0.79 0.20 0.004 1.73
Iroquois related homeobox 3 (Drosophila)
[Irx3_predicted]
ENSRNOT00000043254 0.809 0.41 0.031 1.74
Hdac5 protein (Fragment) [Hdac5] ENSRNOT00000028381 0.86 0.70 0.022 1.81
Ribonuclease, rnase A family, 1 (pancreatic)
[Rnase1]
NM_001029904 0.90 0.22 0.004 1.86
Ring finger protein 24 [Rnf24_predicted] ENSRNOT00000028869 0.92 0.22 0.037 1.89
Amyloid beta (A4) precursor protein-binding,
family A, member 1 [Apba1]
NM_031779 0.96 0.36 0.044 1.94
CWF19-like 1, cell cycle control (S. Pombe)
[Cwf19l1_predicted]
ENSRNOT00000017202 0.97 0.09 0.044 1.95
Similar to high density lipoprotein-binding protein
[RGD1564237_predicted]
ENSRNOT00000009811 0.98 0.19 0.002 1.97
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Table 2 Up-regulated genes on DNA microarray (Continued)
P21 (CDKN1A)-activated kinase 6 [Pak6_predicted] ENSRNOT00000010471 0.10 0.08 0.036 2.00
Similar to nuclear body associated kinase 1a
[Hipk2_predicted]
XM_342662 1.06 0.66 0.049 2.09
Cationic trypsinogen [LOC286911] NM_173127 1.08 0.07 0.031 2.11
Chac, cation transport regulator-like 1 (E. Coli)
[RGD1560049_predicted]
XM_342497 1.10 0.08 0.033 2.15
NTAK alpha2 [Nrg2] D89996 1.13 0.10 0.042 2.18
Ubiquitin carboxy-terminal hydrolase L1 [Uchl1] NM_017237 1.24 0.26 0.014 2.37
Claudin 19 [cldn19] NM_001008514 1.43 0.12 0.037 2.70
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and 3B).
In order to verify the increased oxidative/nitrosative
stress in ZDF animals, myocardial 3-nitrotyrosine levels
were determined in both groups at week 25. A marker
molecule of peroxynitrite, 3-nitrotyrosine level was sig-
nificantly elevated in the heart of ZDF animals showing
increased cardiac oxidative/nitrosative stress (Figure 4).
Gene expression profiles measured using cDNA
microarrays and by qRT-PCR
Among the 14921 genes surveyed, 10244 genes were
expressed on the cDNA microarray, and 85 genes whose
expression was > ~1.7-fold up- or down-regulated (log2
ratio <-0.75 or log2 ratio >0.75) in hearts of ZDF rats rela-
tive to levels of lean control rats showed significant change
in expression. According to our results, 49 genes showed
down-regulation (Table 1) and 36 genes showed up-
regulation in hearts of ZDF rats (Table 2). The expression
change of selected 23 genes was validated by qRT-PCR
(Table 3 and 4), 18 of these 23 genes have been confirmed
by qRT-PCR (Table 3). Most of these genes have not been
shown to be involved in the development of cardiovascular
complications of metabolic syndrome yet.
Gene ontology analysis
In order to further determine the biological significance
and functional classification of differentially expressed
genes due to metabolic syndrome, GO analysis was
performed (Table 5). GO is a bioinformatics initiative with
the aim of standardizing the representation of genes and
gene products providing a controlled and regularly updated
vocabulary of terms for gene product characteristics and
annotation data. GO analysis is suitable for identifying sig-
nificantly enriched GO terms related to multiple genes and
for discovering enriched functionally related gene groups. A
single gene can belong to different categories. Out of the 85
genes significantly altered by metabolic syndrome in our
present study, 68 genes with known function were submit-
ted to GO analysis. The rest of the 85 genes were either un-
known expressed sequence tags or unrecognized by the
GO analysis database. The 68 analyzed genes were classifiedinto three main categories such as (i) cellular metabolic
process, (ii) developmental process and (iii) localization
including transport (Table 5).
Discussion
In the present study, our aim was to investigate whether
cardiac gene expression is influenced by metabolic syn-
drome. Here we show several characteristics of metabolic
syndrome in 25 weeks old male ZDF rats including obesity,
fasting hyperglycemia, hyperlipidemia, hyperinsulinemia,
insulin resistance, and impaired glucose tolerance as well as
increased cardiac nitrosative stress. In the present study, we
demonstrate for the first time in the literature that meta-
bolic syndrome influences cardiac gene expression pattern
by altering transcript levels of several genes. We identified
85 genes which were differentially expressed dominantly in
the myocardium [47,48] of ZDF rats compared to normal
controls. Many of these differentially expressed genes are
known to be involved in multiple cell functions, including
metabolism, stress response, signal transduction, regulation
of transcription, cytoskeletal structure, cell adhesion, mem-
brane proteins, receptors and others. The majority of these
genes have not been related to metabolic syndrome yet,
and therefore, characterization of the functional effects of
these genes on the heart in metabolic syndrome is sug-
gested in future mechanistic studies.
Our present findings showing that 25 week old male
ZDF rats develop insulin resistance with hyperinsuline-
mia, hyperglycemia and impaired HOMA-index are in
accordance with previous studies [32-34,49,50]. Both
metabolic syndrome and type 2 diabetes mellitus are
associated with insulin resistance, hyperinsulinemia and
hyperglycemia. Insulin resistance has been reported to
be influenced by certain genetic factors and nutrients in
patients suffering from metabolic syndrome [51]. It has
been proposed that myocardial SERCA2a overexpression
stimulated by hyperinsulinemia plays an important role
in the cardiac adaptation in ZDF animals [52]. Others
have shown that GLUT4 content decreases along with
the development of insulin resistance in the myocardium
and other insulin sensitive tissues which might play a
key role in the impaired glycemic homeostasis in
Table 3 QRT-PCR
Description [Gene symbol] Acc. No.: DNA MICROARRAY QRT-PCR Confirmed
Fold change p value Ratio (SD) Fold change Regulation
ADAM metallopeptidase with
thrombospondin type 1 motif, 1
[Adamts1]
NM_024400 −7.16 0.1295 0.58 (0.09) −1.72 down yes
heat shock 70kD protein 1A [Hspa1a] NM_031971 −3.59 0.0045 0.34 (0.06) −2.94 down yes
similar to 60 kDa heat shock protein
mitochondrial precursor [Hsp60]
XR_085659 −3.11 0.0565 0.64 (0.10) −1.56 down yes
interleukin 18 [Il18] NM_019165 −2.60 0.0066 0.91 (0.15) −1.10 no change no
ATPase, (Na+)/K+ transporting, beta 4
polypeptide [Atp1b4]
NM_053381 −2.60 0.0031 0.37 (0.06) −2.70 down yes
argininosuccinate synthetase [Ass] NM_013157 −2.51 0.0007 0.29 (0.05) −3.42 down yes
myosin IXA [Myo9a] NM_134335 −2.40 0.0018 0.90 (0.15) −1.11 no change no
glycine C-acetyltransferase (2-amino-3-
ketobutyrate-coenzyme A ligase) [Gcat]
NM_001024277 −2.22 0.0063 0.33 (0.03) −3.07 down yes
activating transcription factor 3 [Atf3] NM_012912 −2.05 0.0044 0.35 (0.06) −2.85 down yes
similar to chondroitin sulfate GalNAcT-
2 [RGD1563660_predicted]
ENSRNOT00000019778 −1.87 0.0170 0.92 (0.15) −1.09 no change no
S100 calcium binding protein A3
[S100a3]
NM_053681 −1.87 0.0281 1.74 (0.28) 1.74 up no
sushi, nidogen and EGF-like domains 1
[Sned1]
NM_001167842 −1.83 0.0407 0.42 (0.07) −2.36 down yes
G protein-coupled receptor 37 [Gpr37] NM_057201 −1.82 0.0297 1.08 (0.18) 1.08 no change no
angiopoietin-like 4 [Angptl4] NM_199115 1.78 0.0073 2.90 (0.47) 2.90 up yes
glutathione S-transferase Yc2 subunit
[Yc2]
NM_001009920 1.82 0.0017 2.21 (0.36) 2.21 up yes
ribonuclease, RNase A family, 1
(pancreatic) [Rnase1]
NM_001029904 1.86 0.0039 2.68 (0.44) 2.68 up yes
similar to high density lipoprotein-
binding protein
[RGD1564237_predicted]
ENSRNOT00000009811 1.97 0.0020 2.73 (0.44) 2.73 up yes
3-hydroxy-3-methylglutaryl-Coenzyme
A synthase 2[Hmgcs2]
NM_173094 2.07 0.0036 2.42 (0.39) 2.42 up yes
similar to tetracycline transporter-like
protein [RGD1311900_predicted]
ENSRNOT00000017386 2.24 0.1671 1.29 (0.21) 1.29 no change no
ubiquitin carboxy-terminal hydrolase
L1 [Uchl1]
NM_017237 2.37 0.0144 2.50 (0.41) 2.50 up yes
ATPase, H+/K+ transporting,
nongastric, alpha polypeptide [Atp12a]
NM_133517 2.61 0.0061 3.06 (0.50) 3.06 up yes
phospholipase A2, group VII (platelet-
activating factor acetylhydrolase,
plasma) [Pla2g7]
NM_001009353 2.74 0.0411 4.25 (0.69) 4.25 up yes
cytosolic acyl-CoA thioesterase 1 [Cte1] NM_031315 3.69 0.0028 3.16 (0.51) 3.16 up yes
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has been reported to activate p53 and p53-regulated
genes involving the local renin-angiotensin system which
leads to increased apoptosis of cardiomyocytes [54].
Moreover, postprandial hyperglycemia has been shown
to play an important role on the onset and development
of heart failure in humans [55]. Chronic hyperglycemia
has been reported to enhance the vasoconstrictor re-
sponse by Rho-kinase [56]. Hyperglycemia itself hasbeen shown to increase rat aortic smooth muscle cell
growth and gene expression in diabetes mellitus [57].
Some drugs e.g. statins [57] and nitrates [58] have been
reported to abolish hyperglycemia induced vasoconstric-
tion. These aforementioned studies, in agreement with
our present study, suggest that metabolic serum para-
meters may influence cardiac gene expression pattern
and may lead to functional consequences. Although we
have not measured blood pressure in our study, ZDF
Table 4 Primers to QRT-PCR
Gene symbol Gene description Acc. No.: Forward Reverse
Adamts1 ADAM metallopeptidase with thrombospondin
type 1 motif, 1
NM_024400 aaaggcattggctacttctttg ggactacagggagtgccatc
Hspa1a heat shock 70kD protein 1A (Hspa1a) NM_031971 tggcccattaaataagaaccaa cgaaggcgtagagattccag
Hsp60 similar to 60 kDa heat shock protein,
mitochondrial precursor (Hsp60)
XR_085659 gctacaatttctgcaaacagagac cattaggggttttcccatcc
Il18 interleukin 18 (Il18) NM_019165 gcctgatatcgaccgaaca ccttccatccttcacagatagg
Atp1b4 ATPase, (Na+)/K+ transporting, beta 4
polypeptide (Atp1b4)
NM_053381 acttggcagcgttatgtcatt catttcctcttgaagactgtcattat
Ass argininosuccinate synthetase (Ass) NM_013157 ccaccggcttcatcaatatc tgctctgaaggcgatggta
Myo9a myosin IXA (Myo9a) NM_134335 cactctgagctagggcctgt actgaagaaaatcgttgtgacg
Gcat glycine C-acetyltransferase (2-amino-3-
ketobutyrate-coenzyme A ligase) (Gcat)
NM_001024277 gctggcctcatttctactcg gcgggctatcttggcttc
Atf3 activating transcription factor 3 NM_012912 tgtcagtcaccaagtctgaggt cacttggcagcagcaattt
RGD1563660_pred similar to chondroitin sulfate GalNAcT-2 (pred) NM_001106616 tcgtctatgccaaccagga tctccaaaaaccagagtccttt
S100a3 S100 calcium binding protein A3 NM_053681 agcagcagcagcagttga ggtacacacgatggcagcta
Sned1 sushi, nidogen and EGF-like domains 1 (Sned1) NM_001167842 cctggtaccgtgtgaccttc caccgtttggaatgtgttga
Gpr37 G protein-coupled receptor 37 NM_057201 ccaagaagtggcttttggaa agtgacacccagagaagctacc
Angptl4 angiopoietin-like 4 NM_199115 tctccaccatttttggtcaac gttcaggcgtctctgaatcac
Yc2 glutathione S-transferase Yc2 subunit NM_001009920 tctgaaaactcgggatgacc accagcttcatcccgtca
Rnase1 ribonuclease, RNase A family, 1 (pancreatic) NM_001029904 actgactgccgcctgaag ttctggctgtcagtggttgt
RGD1311900_pred
RGD
similar to tetracycline transporter-like protein ENSRNOT00000017386 gcactcactgcctatgttgg cctggagaaccatagctgga
RGD1564237_pred
RGD
similar to high density lipoprotein-binding
protein
ENSRNOT00000009811 ggaggagaccaacatgatcc agcacttggcagaagtagcac
Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase
2
NM_173094 cctggcctcacttctctcc ggagaaggctccaatcctg
Uchl1 ubiquitin carboxy-terminal hydrolase L1 NM_017237 attcaggcagcccatgact gaaattcactttgtcgtctaccc
Atp12a ATPase, H+/K+ transporting, nongastric, alpha
polypeptide
NM_133517 gcatcattgtggctaacgtg ccgtcagtgacagggtaaca
Pla2g7 phospholipase A2, group VII (platelet-activating
factor acetylhydrolase
NM_001009353 actggcaagacccttcttttt gacatcaccgattggagctt
Cte1 cytosolic acyl-CoA thioesterase 1 NM_031315 gtgcacgagcgtcacttc gaaagggcccaggttctg
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sure at ages similar to that of used in the present
study [59-61]
In our present study, several genes related to metabol-
ism were found to be affected in the hearts of ZDF rats
as compared to controls. A group of these altered genes
is involved in ketone body metabolism (down-regulation of
3-hydroxybutyrate dehydrogenase, type 1; up-regulation of
2-amino-3-ketobutyrate-coenzyme A ligase and 3-hydroxy-
3-methylglutaryl-coenzyme A synthase 2). Decreased rate
of ketone body oxidation and decreased activity of 3-
hydroxybutyrate dehydrogenase activity in streptozotocin-
induced diabetic rat hearts have been shown previously
[62]. In our present study, metabolic syndrome also
influenced expression of genes related to metabolism
of carbohydrates (down-regulation of dicarbonyl L-xylulose
reductase and up-regulation of mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase,
isozyme C, pred) as well as lipids (up-regulation of acyl-
CoA thioesterase 1 and cytosolic acyl-CoA thioesterase
1). Similarly to our present findings, gene expression of
cytosolic acyl-CoA thioesterase 1 has been reported to
be up-regulated by high fat diet [63] or STZ-induced
diabetes [63] in the rat myocardium. A third group of
differentially expressed metabolic genes in our present
study (down-regulation of argininosuccinate synthetase
and up-regulation of angiopoietin-like 4) in ZDF hearts
is potentially regulated by oxidative and nitrosative
stress which is increased in metabolic diseases e.g.
hyperlipidemia [13,40,64], hypertension [65], insulin
resistance [66], diabetes mellitus [67] and in the heart of
ZDF rats as shown in previous [42] as well as in the
present study. High TNF-alpha concentrations [68] and
insulin resistance [69,70] in endothelial cells have been
Table 5 Gene ontology analysis
Category GO ID Level Term Count % p value Genes (gene symbols)
GOTERM_BP_ALL GO:0009987 02 cellular process 47 55,3 0,035 ACAN, ACOT1, ACOT7, ANGPTL4, APBA1, ARID2, ARNTL,
ASS1, ATF3, ATP1B4, ATP12A,BCL2A1D, BEX1, CAMK2G,
CBR1, CHRNG, COL24A1, CSGALNACT1, CTGF, DCXR,
DLG4, DUSP3, EXO1, GSTA5, HAP1, HDAC5, HEY2, HIPK2,
HMGCS2, HSPA1A, HSPA1B, HNRPLL, IRX3, LOC360228,
LOC501189, NGFR, NNAT, NTSR2, PCK2, SNED1, SPTBN2,
ST8SIA4, STRBP, TAF13, TGM1, TYMS, UCHL1
GOTERM_BP_ALL GO:0009266 04 response to
temperature stimulus
5 5,9 0,013 CIRBP, HSPA1A, HSPA1B, IL18, NGFR
GOTERM_BP_ALL GO:0042180 04 cellular ketone
metabolic process
9 10,6 0,004 ACOT1, ACOT7, ARID2, ASS1, ATF3, CBR1, CSGALNACT1,
HNRPLL, PCK2
GOTERM_BP_ALL GO:0006082 04 organic acid metabolic
process
8 9,4 0,014 ACOT1, ACOT7, ARID2, ASS1, ATF3, CSGALNACT1,
HNRPLL, PCK2
GOTERM_BP_ALL GO:0019752 05 carboxylic acid
metabolic process
8 9,4 0,014 ACOT1, ACOT7, ARID2, ASS1, ATF3, CSGALNACT1,
HNRPLL, PCK2
GOTERM_BP_ALL GO:0043436 05 oxoacid metabolic
process
8 9,4 0,014 ACOT1, ACOT7, ARID2, ASS1, ATF3, CSGALNACT1,
HNRPLL, PCK2
GOTERM_BP_ALL GO:0034637 05 cellular carbohydrate
biosynthetic process
3 3,5 0,039 ATF3, CSGALNACT1, PCK2
GOTERM_BP_ALL GO:0051346 06 negative regulation of
hydrolase activity
4 4,7 0,023 ANGPTL4, BCL2A1D, HSPA1A, HSPA1B,
GOTERM_BP_ALL GO:0008284 06 positive regulation of
cell proliferation
6 7,1 0,039 ATF3, BEX1, HEY2, HIPK2, IL18, NGFR
GOTERM_BP_ALL GO:0048489 07 synaptic vesicle
transport
3 3,5 0,017 APBA1, DLG4, SPTBN2
GOTERM_BP_ALL GO:0032502 02 developmental process 25 29,4 0,001 ACAN, ANGPTL4, APBA1, ASS1, ATF3, BCL2A1D, BEX1,
CBR1, CTGF, DLG4, EXO1, HAP1, HEY2, HIPK2, IL18, IRX3,
KLK14, LOC360228, NGFR, NNAT, NRG2, ODZ4, STRBP,
TGM1, UCHL1
GOTERM_BP_ALL GO:0048869 03 cellular developmental
process
15 17,6 0,012 ACAN, ANGPTL4, ATF3, BCL2A1D, BEX1, CTGF, DLG4,
HEY2, IRX3, LOC360228, NGFR, NNAT, STRBP, TGM1, UCHL1
GOTERM_BP_ALL GO:0007275 03 multicellular organismal
development
23 27,1 0,001 ACAN, ANGPTL4, APBA1, ASS1, BCL2A1D, BEX1, CBR1,
CTGF, DLG4, EXO1,HEY2, HAP1, HIPK2, IL18, IRX3, KLK14,
NGFR, NNAT, NRG2, ODZ4, STRBP, TGM1, UCHL1
GOTERM_BP_ALL GO:0048856 03 anatomical structure
development
19 22,3 0,013 ACAN, ANGPTL4, ASS1, BCL2A1D, BEX1, CBR1, CTGF,
DLG4, EXO1, HAP1, HEY2, IL18, IRX3, KLK14, NGFR,
NNAT, ODZ4, TGM1, UCHL1
GOTERM_BP_ALL GO:0048731 04 system development 18 21,1 0,016 ACAN, ANGPTL4, ASS1, BCL2A1D, BEX1, CBR1, CTGF,
DLG4, EXO1, HAP1, HEY2, IL18, IRX3, KLK14, NGFR,
NNAT, TGM1, UCHL1
GOTERM_BP_ALL GO:0030154 04 cell differentiation 15 17,6 0,009 ACAN, ANGPTL4 ATF3, BCL2A1D, BEX1, CTGF, DLG4,
HEY2, IRX3, LOC360228, NGFR, NNAT, STRBP, TGM1, UCHL1
GOTERM_MF_ALL GO:0003824 02 catalytic activity 30 35,3 0,037 ACOT1, ACOT7, ARID2, ASS1, ATP1B4, ATP12A ,BDH1,
CAMK2G, CBR1, CSGALNACT1, DCXR, DUSP3, EXO1,
GCAT, GSTA5, HDAC5, HIPK2, HMGCS2, KLK14,
LOC286911, LOC501189, MYO9A, PCK2, PLA2G7, RAB7A,
RNASE1, ST8SIA4, TYMS, TGM1, UCHL1
GOTERM_MF_ALL GO:0016788 04 hydrolase activity,
acting on ester bonds
7 8,2 0,041 ACOT1, ACOT7, DUSP3, EXO1, PLA2G7, RNASE1, UCHL1
GOTERM_MF_ALL GO:0016790 05 thiolester hydrolase
activity
3 3,5 0,047 ACOT1, ACOT7, UCHL1
GOTERM_CC_ALL GO:0031974 02 membrane-enclosed
lumen
13 14,5 0,032 ARNTL, ASCL3, ASCL3_PREDICTED, ATF3, BDH1, CIRBP,
DUSP3, HIPK2, HMGCS2, NGFR, SPTBN2, SUPT16H, TAF13
GOTERM_CC_ALL GO:0044421 03 extracellular region part 8 9,6 0,044 ACAN, ANGPTL4, COL24A1, CTGF, LOC286911,
LOC360228, IL18, KLK14
GOTERM_CC_ALL GO:0031090 04 organelle membrane 11 12,0 0,032 ASS1, CAMK2G, CSGALNACT1, BDH1, DLG4, GCAT,
GSTA5, HIPK2, HMGCS2, LOC501189, ST8SIA4
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Table 5 Gene ontology analysis (Continued)
GOTERM_CC_ALL GO:0043233 04 organelle lumen 13 15,3 0,027 ARNTL, ASCL3, ASCL3_PREDICTED, ATF3, BDH1, CIRBP,
DUSP3, HIPK2, HMGCS2, NGFR, SPTBN2, SUPT16H, TAF13
GOTERM_CC_ALL GO:0070013 06 intracellular organelle
lumen
13 15,3 0,021 ARNTL, ASCL3, ASCL3_PREDICTED, ATF3, BDH1, CIRBP,
DUSP3, HIPK2, HMGCS2, NGFR, SPTBN2, SUPT16H, TAF13
GOTERM_CC_ALL GO:0005654 06 nucleoplasm 9 10,6 0,045 ARNTL, ASCL3, ASCL3_PREDICTED, CIRBP, DUSP3,
HIPK2, NGFR, SUPT16H, TAF13
GOTERM_CC_ALL GO:0031981 07 nuclear lumen 12 14,1 0,029 ARNTL, ASCL3, ASCL3_PREDICTED, ATF3, CIRBP, DUSP3,
HIPK2, NGFR, SPTBN2, SUPT16H, TAF13
GOTERM_CC_ALL GO:0030139 08 endocytic vesicle 3 3,5 0,034 CAMK2G, DLG4, RAB7A
Significantly enriched gene ontology (GO) terms in the population of genes with altered expression due to metabolic syndrome. GO analysis determines the
biological significance of differentially expressed genes that can be used to determine the functional classification of the genes, the expression of which have
been significantly up- or down-regulated. Major functional categories of GO terms were separated by horizontal lines, subcategories are represented by level on
gene tree.
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ling enzyme, argininosuccinate synthetase. Overexpres-
sion of hepatic angiopoietin-like 4 gene has been shown
in diabetic mice [71] and up-regulation of this gene has
reported to be induced by fatty acids via PPAR-gamma
in muscle tissue [72]. Additionally, insulin has been
shown to down regulate angiopoietin-like 4 in adipo-
cytes [73] and this down-regulation could be attenuated
in insulin resistance [73].
Members of another functional gene cluster that is
related to stress response showed altered expression in
ZDF hearts as compared to controls in the present study
(down-regulation of heat shock 70 kDa protein 1A; similar
to 60 kDa heat shock protein, mitochondrial precursor;
interleukin 18 and up-regulation of cold inducible RNA
binding protein; glutathione S-transferase Yc2 subunit). We
have previously shown that hyperlipidemia inhibits cardiac
heat shock response [36]. Moreover, heat shock proteins,
especially Hsp60, were found to have protective effect
against cardiac oxidative and nitrosative stress [74]. Accord-
ing to the attenuated expression of heat shock protein 60
and 70 in our present study, metabolic syndrome with well-
known increased cardiovascular oxidative and nitrosative
stress [41,42] due to hyperlipidemia [64], hypertension [65]
and hyperglycemia [66,67] might interfere with cardiac heat
shock response. Glutathion S-transferase catalyzes the con-
jugation of reduced glutathione on a wide variety of sub-
strates [75] including reactive oxygen and nitrogen species
[76]. Interestingly, we have found here the overexpres-
sion of glutathione S-transferase in metabolic syndrome
similarly to the up-regulation of this gene in cholesterol
diet-induced hyperlipidemia in our previous study [77].
Additionally, the absence of cardiomyopathy in diabetes
has been reported to be accompanied by increased glutathi-
one S-transferase activity in rat hearts [78]. These results
suggest that up-regulation of glutathione S-transferase may
be an adaptive response in metabolic syndrome to
antagonize elevated oxidative/nitrosative stress in the myo-
cardium. Elevated circulating interleukin 18 levels have
been reported to be associated with metabolic syndromeindependent of obesity and insulin resistance [79], however,
in our present study; the myocardial gene expression of
interleukin 18 was down-regulated.
In the present study, we have also shown altered ex-
pression of several genes related to signal transduction
and regulation of transcription in the hearts of ZDF rats
as compared to controls (e.g. down-regulation of activat-
ing transcription factor 3; sushi, nidogen and EGF-like
domains 1 (insulin responsive sequence DNA binding
protein-1) and up-regulation of calcium/calmodulin-
dependent protein kinase II gamma; phospholipase A2,
group VII). Interestingly, in our present study, an adap-
tive and oxidative stress-responsive transcription factor
[80-82], activating transcription factor 3 showed down-
regulation in the heart in metabolic syndrome. Although,
enhanced expression of activating transcription factor 3
has been reported to play a role in diabetic angiopathy
[80], in stress-induced beta cell dysfunction [83,84] and
hepatic LDL receptor down-regulation [85,86], its car-
diac role in metabolic syndrome has not been implicated
yet. Another stress inducible and regulator gene of eicosa-
noid biosynthesis, the phospholipase A2, group VII gene
was up regulated in our present study in ZDF rat hearts. In-
crease of the expression of this gene was previously shown
in ZDF rats in the liver and suggested to be a factor in the
development of chronic low-grade inflammation in meta-
bolic syndrome [87]. In our present study, a regulator gene
of insulin action, the insulin responsive sequence DNA
binding protein-1 showed down-regulation in metabolic
syndrome in ZDF rat hearts. Down-regulation of this gene
has been previously shown in the liver of diabetic [88]
and obese [88] rats. However, it is unclear whether
decreased expression of insulin responsive sequence
DNA binding protein-1 is a consequence of insulin
resistance or contributes to hyperglycemic phenotype.
Calcium/calmodulin-dependent protein kinase II gamma
showed up-regulation in ZDF hearts in our present
study. This gene was reported to potentially mediate
cardiac hypertrophy in pressure overload hypertension
in mouse hearts [89].
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tional cluster of membrane proteins or receptors showed
altered expression in ZDF hearts as compared to controls
(e.g. down-regulation of ATPase, (Na+)/K+ transporting,
beta 4 polypeptide; G protein-coupled receptor 37 and up-
regulation of ATPase, H+/K+ transporting, nongastric,
alpha polypeptide; Huntingtin-associated protein 1). Inter-
estingly, here we have found gene expression changes of
two members of the X,K-ATP-ase family due to metabolic
syndrome. Surprisingly, ATPase, (Na+)/K+ transporting,
beta 4 polypeptide showed down-regulation in obese
ZDF rat hearts characterized by marked hyperlipid-
emia in the current study, however, this gene showed
up-regulation in our previous study in cholesterol-
induced hyperlidemia in the rat myocardium [77].
Additionally, it has been shown in the heart of spon-
taneously hypertensive rats that the microsomal Na+,
K(+)-ATPase activity is reduced [90].
Another set of genes related to the functional cluster of
structural proteins was found to be regulated differentially
in hearts of ZDF rats as compared to controls (e.g. down-
regulation of myosin IXA and similar to collagen, type
XXIV, alpha 1 (pred) and up-regulation of spectrin beta 3
and aggrecan 1). To our current knowledge, we are the first
in the literature demonstrating cardiac gene expression
changes of a novel epithelial extracellular matrix compo-
nent [91], similar to collagen type XXIV; a cell migration
regulator molecule [92], myosin IXA; a membrane stabilizer
molecule [93], spectrin beta 3 and an extracellular
matrix component proteoglycan [94], aggrecan 1, due to
metabolic syndrome.
Some of the genes showing altered expression in ZDF rat
hearts in the present study were not related to specific
functional clusters or indicated as yet uncharacterized, pre-
dicted genes and fragments, the relevance of which should
not be ignored. Many of these genes are reported for the
first time in the literature to show altered expression in
the heart due to metabolic syndrome including down-
regulation e.g. of disintegrin-like and metallopeptidse
(reprolysin type) with thrombospondin type 1 motif; G
protein-coupled receptor 107 (predicted); S100 calcium
binding protein A3; kallikrein 14 (predicted); neuronatin;
connective tissue growth factor and up-regulation e.g. of
amyloid beta (A4) precursor protein-binding, family A,
member 1; similar to high density lipoprotein-binding
protein (predicted); cationic trypsinogen; ubiquitin carboxy-
terminal hydrolase L1.
In order to strengthen our results obtained by micro-
array analysis, and to provide some functional assessment,
we have performed GO analysis on the genes showing
altered expression due to metabolic syndrome. Significantly
enriched GO terms were classified into three main cate-
gories including (i) cellular metabolic process, (ii) develop-
mental process, and (iii) cellular localization. These resultsshowed that metabolic syndrome may significantly affect
several major biological processes, especially genes related
to cellular metabolic processes and development (Table 5).
Our study is not without limitations. Our results regard-
ing altered cardiac gene expression due to metabolic syn-
drome are based on determinations of approximately
15000 cardiac transcript levels, however, confirmation of
gene expression changes at the protein level and direct
measurement of the full rat transcriptome should be per-
formed in the future. Moreover, additional studies provid-
ing more in-depth mechanistic insight and functional
assessment should be carried out. Although our study does
not specify which cell type (i.e. cardiomyocyte, fibroblast,
smooth muscle cell, etc.) may be responsible for the
observed alterations of cardiac gene expression due to
metabolic syndrome, contribution of cardiomyocytes is
likely the most significant [47,95].
In summary, we have found that 25 weeks old male
ZDF rats develop severe metabolic syndrome and we
have demonstrated for the first time that metabolic
syndrome is associated with profound modifications of
the cardiac transcriptome. Several of the genes showing
altered expression in the hearts of ZDF rats have not
been implicated in metabolic syndrome previously. We
conclude that metabolic syndrome alters the gene ex-
pression pattern of the myocardium which may be
involved in the development of cardiac pathologies in
the state of metabolic syndrome. Based on our exploratory
results, future studies should be carried out to investigate
the precise role of specific genes in the development of car-
diac consequences of metabolic syndrome to obtain deeper
mechanistic insight.
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